title: Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up.
authors.forename: L
authors.initials: L
authors.lastname: Amselem
authors.forename: E
authors.initials: E
authors.lastname: Cervera
authors.forename: M
authors.initials: M
authors.lastname: Díaz-Llopis
authors.forename: J
authors.initials: J
authors.lastname: Montero
authors.forename: M
authors.initials: M
authors.lastname: Garcia-Pous
authors.forename: P
authors.initials: P
authors.lastname: Udaondo
authors.forename: S
authors.initials: S
authors.lastname: García-Delpech
authors.forename: D
authors.initials: D
authors.lastname: Salom
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000473:pathology; D002830:Choroid Neoplasms / Q000556:secondary*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008875:Middle Aged; D016896:Treatment Outcome; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab